‘By next summer, Covid will be close to a bad memory’

The daily toll of new infections. The number of hospitalisations. The numbers in ICU. The R-0 number. The cases per 100,000 people. For more than eight months now, almost every aspect of our lives has been dominated by daily, grim readings of the Covid-19 data.

And then, last Monday at 11.45am, a press release featuring a whole new set of numbers landed in news editors’ inboxes: 43,538 – the number of people enrolled in the trial for Pfizer and BioNTech’s BNT1 62b2 vaccine; 94 – the number of confirmed cases of Covid-19 evaluated; 90 per cent – the vaccine’s estimated efficacy.

One of the intriguing next stages will involve human challenge trials – clinical trials in which healthy volunteers are exposed to Covid-19 in a controlled setting.

Open Orphan (LON:ORPH) was founded in 2017, with the goal of rapidly building Europe’s leading pharma services company by a management team with extensive industry and financial expertise. The company comprises of two commercial specialist CRO services businesses (Venn Life Sciences and hVIVO) and is also developing a genomics data platform business (Genomic Health Data). 

Click to view all articles for the EPIC:
Or click to view the full company profile:
Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Open Orphan Plc

More articles like this

Open Orphan Plc

Open Orphan article published in Drug Discovery Today

Open Orphan plc (LON:ORPH), a rapidly growing specialist pharmaceutical services clinical research organization (CRO) and a world leader in vaccine and antiviral testing using human challenge clinical trials, has announced an article submission has been published in Drug Discovery Today,

Open Orphan Plc

Codagenix and SII begin dosing in Phase I Covid-19 vaccine trial

Biotechnology firm Codagenix and Serum Institute of India (SII) have dosed the first patient in Phase I clinical trial of a single-dose, intranasal Covid-19 vaccine, COVI-VAC. Developed with Codagenix’s Synthetic Attenuated Virus Engineering (SAVE) platform, the vaccine can

Open Orphan Plc

Nasal Covid vaccine can be potential game-changer

Public health experts believe that intranasal vaccines for coronavirus, administered through nose rather than muscles, can be a potential gamechanger in Indias fight against the coronavirus pandemic. The nasal vaccine is different from two intramuscular vaccines which recently